Brexpiprazole
Brexpiprazole is a pharmaceutical drug with 56 clinical trials. Currently 4 active trials ongoing. Historical success rate of 91.5%.
Success Metrics
Based on 43 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
8
Mid Stage
40
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
86.0%
43 of 50 finished
14.0%
7 ended early
4
trials recruiting
56
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Longitudinal PET Imaging of Antipsychotic Binding to the Dopamine-3 Receptor in Schizophrenia
Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)
Brexpiprazole in Alcohol Use Disorder
Real-life Assessment of Abilify Maintena + Rexult in Schizophrenia
Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia
Clinical Trials (56)
Longitudinal PET Imaging of Antipsychotic Binding to the Dopamine-3 Receptor in Schizophrenia
Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)
Brexpiprazole in Alcohol Use Disorder
Real-life Assessment of Abilify Maintena + Rexult in Schizophrenia
Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia
Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder
Real-life Assessment of Brexpiprazole (Rexulti) in Schizophrenia and in Depressive Disorders
Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD
Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder
Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder
Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia
Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication
Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)
Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
A Study of Brexpiprazole in Patients With Major Depressive Disorder
Brexpiprazole Treatment for Bipolar I Depression
A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder
Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148
A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 56